Sonja C. S. Simon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sonja C. S. Simon has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Jochen S. Utikal
German Cancer Research Center (DKFZ) Skin Cancer Unit Heidelberg Germany
2 shared publications- Cristian Vladescu
National Institute for Health Services Management, 030167 Bucharest, Romania
1 shared publication - Daniel Schaffert
Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
1 shared publication - Igor Bibi
Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
1 shared publication - Jan Leipe
Rheumatology Department, Kiel Campus, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
1 shared publication - Johannes Benecke
Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
1 shared publication
Latest Publications
- Open Access
- 15 December 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (12) , 1272
AutoML-Driven Insights into Patient Outcomes and Emergency Care During Romania’s First Wave of COVID-19
Background: The COVID-19 pandemic severely impacted healthcare systems, affecting patient outcomes and resource allocation. This study applied automated machine learning (AutoML) to analyze key health outputs, such as discharge conditions, mortality, and COVID-19 cases, with the goal of improving responses to future crises. Methods: AutoML was used to train and validate models on an ICD-10 dataset covering the first wave of COVID-19 in Romania (January–September 2020). Results: For discharge outcomes, Light Gradient Boosted models achieved an F1 score of 0.9644, while for mortality 0.7545 was reached. A Generalized Linear Model blender achieved an F1 score of 0.9884 for “acute or emergency” cases, and an average blender reached 0.923 for COVID-19 cases. Older age, specific hospitals, and oncology wards were less associated with improved recovery rates, while mortality was linked to abnormal lab results and cardiovascular/respiratory diseases. Patients admitted without referral, or patients in hospitals in the central region and the capital region of Romania were more likely to be acute cases. Finally, counties such as Argeş (South-Muntenia) and Brașov (Center) showed higher COVID-19 infection rates regardless of age. Conclusions: AutoML provided valuable insights into patient outcomes, highlighting variations in care and the need for targeted health strategies for both COVID-19 and other health challenges.
- 15 December 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (12) , 1272
Open AccessAutoML-Driven Insights into Patient Outcomes and Emergency Care During Romania’s First Wave of COVID-19
Background: The COVID-19 pandemic severely impacted healthcare systems, affecting patient outcomes and resource allocation. This study applied automated machine learning (AutoML) to analyze key health outputs, such as discharge conditions, mortality, and COVID-19 cases, with the goal of improving responses to future crises. Methods: AutoML was used to train and validate models on an ICD-10 dataset covering the first wave of COVID-19 in Romania (January–September 2020). Results: For discharge outcomes, Light Gradient Boosted models achieved an F1 score of 0.9644, while for mortality 0.7545 was reached. A Generalized Linear Model blender achieved an F1 score of 0.9884 for “acute or emergency” cases, and an average blender reached 0.923 for COVID-19 cases. Older age, specific hospitals, and oncology wards were less associated with improved recovery rates, while mortality was linked to abnormal lab results and cardiovascular/respiratory diseases. Patients admitted without referral, or patients in hospitals in the central region and the capital region of Romania were more likely to be acute cases. Finally, counties such as Argeş (South-Muntenia) and Brașov (Center) showed higher COVID-19 infection rates regardless of age. Conclusions: AutoML provided valuable insights into patient outcomes, highlighting variations in care and the need for targeted health strategies for both COVID-19 and other health challenges.
- Open Access
- 23 March 2023
- Published by Scientific Archives
- Vol. 5 (1) , 14-18
From Lipase Elevation to Diabetes – Pancreatic Involvement during Immune Checkpoint Inhibition
Nowadays, as a standard of care treatment of several cancers, immune checkpoint inhibitors have changed the field of oncology. However, their empowerment of T cell
- 23 March 2023
- Published by Scientific Archives
- Vol. 5 (1) , 14-18
Open AccessFrom Lipase Elevation to Diabetes – Pancreatic Involvement during Immune Checkpoint Inhibition
Nowadays, as a standard of care treatment of several cancers, immune checkpoint inhibitors have changed the field of oncology. However, their empowerment of T cell
- Open Access
- 7 March 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1111119
Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation
Mutations in the NRAS gene are common alterations in malignant melanoma. However, there are no specific treatment options approved for NRAS-mutated melanoma patients besides immune checkpoint inhibition. Since preclinical data suggests a synergistic effect of a MEK inhibitor (MEKi) and the oncolytic virus talimogene laherparepvec (T-VEC), we have treated three melanoma patients with this combination. All of the three patients had been suffering from recurring cutaneous and subcutaneous in-transit metastases. Upon treatment one patient (case 1) presented full regression of locoregional metastases and remained progression-free until date, for almost three years. The second patient (case 2) showed a partial regression of painful gluteal satellite metastases but died from brain metastases. The third patient (case 3) showed a durable response of locoregional metastases for seven months. The combination treatment was well tolerated with common adverse events known for each single agent. This report is the first case series presenting a clinical benefit of the combined T-VEC and MEKi treatment. We suggest the combination of T-VEC and MEKi as an off-label treatment option for patients with NRAS mutations, especially with recurrent in-transit or satellite metastases.
- 7 March 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1111119
Open AccessCase report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation
Mutations in the NRAS gene are common alterations in malignant melanoma. However, there are no specific treatment options approved for NRAS-mutated melanoma patients besides immune checkpoint inhibition. Since preclinical data suggests a synergistic effect of a MEK inhibitor (MEKi) and the oncolytic virus talimogene laherparepvec (T-VEC), we have treated three melanoma patients with this combination. All of the three patients had been suffering from recurring cutaneous and subcutaneous in-transit metastases. Upon treatment one patient (case 1) presented full regression of locoregional metastases and remained progression-free until date, for almost three years. The second patient (case 2) showed a partial regression of painful gluteal satellite metastases but died from brain metastases. The third patient (case 3) showed a durable response of locoregional metastases for seven months. The combination treatment was well tolerated with common adverse events known for each single agent. This report is the first case series presenting a clinical benefit of the combined T-VEC and MEKi treatment. We suggest the combination of T-VEC and MEKi as an off-label treatment option for patients with NRAS mutations, especially with recurrent in-transit or satellite metastases.